Marc Cohen
Direktor/Vorstandsmitglied bei Angiocrine Bioscience, Inc.
Aktive Beziehungen
| Name | Geschlecht | Alter | Unternehmensverbindungen | Zusammenarbeit |
|---|---|---|---|---|
| Paul W. Finnegan | M | 63 |
Angiocrine Bioscience, Inc.
 Angiocrine Bioscience, Inc. Miscellaneous Commercial ServicesCommercial Services Angiocrine Bioscience, Inc. is a clinical-stage biotechnology company based on its novel and proprietary e-cel® platform. The company is based in San Diego, CA. The company is developing multiple e-cel therapies designed to repair damaged tissue from age-related degenerative disease of the musculoskeletal system, immune diseases that attack vessels and tissues, and ischemic diseases involving soft tissue, central nervous system, and the heart. The CEO of the company is Paul W. Finnegan. | - |
| Jeff Jonas | M | 71 |
Angiocrine Bioscience, Inc.
Angiocrine Bioscience, Inc. Miscellaneous Commercial ServicesCommercial Services Angiocrine Bioscience, Inc. is a clinical-stage biotechnology company based on its novel and proprietary e-cel® platform. The company is based in San Diego, CA. The company is developing multiple e-cel therapies designed to repair damaged tissue from age-related degenerative disease of the musculoskeletal system, immune diseases that attack vessels and tissues, and ischemic diseases involving soft tissue, central nervous system, and the heart. The CEO of the company is Paul W. Finnegan. | - |
| David Parkinson | M | 73 |
Angiocrine Bioscience, Inc.
Angiocrine Bioscience, Inc. Miscellaneous Commercial ServicesCommercial Services Angiocrine Bioscience, Inc. is a clinical-stage biotechnology company based on its novel and proprietary e-cel® platform. The company is based in San Diego, CA. The company is developing multiple e-cel therapies designed to repair damaged tissue from age-related degenerative disease of the musculoskeletal system, immune diseases that attack vessels and tissues, and ischemic diseases involving soft tissue, central nervous system, and the heart. The CEO of the company is Paul W. Finnegan. | - |
| Jeffrey L. Port | M | - |
Angiocrine Bioscience, Inc.
Angiocrine Bioscience, Inc. Miscellaneous Commercial ServicesCommercial Services Angiocrine Bioscience, Inc. is a clinical-stage biotechnology company based on its novel and proprietary e-cel® platform. The company is based in San Diego, CA. The company is developing multiple e-cel therapies designed to repair damaged tissue from age-related degenerative disease of the musculoskeletal system, immune diseases that attack vessels and tissues, and ischemic diseases involving soft tissue, central nervous system, and the heart. The CEO of the company is Paul W. Finnegan. | - |
| John R. Jaskowiak | M | - |
Angiocrine Bioscience, Inc.
Angiocrine Bioscience, Inc. Miscellaneous Commercial ServicesCommercial Services Angiocrine Bioscience, Inc. is a clinical-stage biotechnology company based on its novel and proprietary e-cel® platform. The company is based in San Diego, CA. The company is developing multiple e-cel therapies designed to repair damaged tissue from age-related degenerative disease of the musculoskeletal system, immune diseases that attack vessels and tissues, and ischemic diseases involving soft tissue, central nervous system, and the heart. The CEO of the company is Paul W. Finnegan. | - |
Beziehungs-Chart
Beziehungen zu mehreren Unternehmen
Statistik
| Land | Beziehungen | % des Gesamten |
|---|---|---|
| Vereinigte Staaten | 5 | 100,00% |
Alter der Beziehungen
Aktive
Vergangene
Herr
Frau
Aufsichtsräte
Führungskräfte
Ursprung der Beziehungen
- Börse
- Insiders
- Marc Cohen
- Persönliches Netzwerk
